NCT06706206Recruiting
The CACHE Study: Coronary Artery Care in HaEmophilia
Source: ClinicalTrials.gov · Last updated 11 Mar 2026
Brief summary (registry, in English)
The investigators will use state-of-the-art imaging to look at heart disease in people with haemophilia. Haemophilia is an inherited disorder in which blood does not clot properly because of lack of a key 'glue' blood component (chemicals known as factor VIII or IX). People with haemophilia are 40% less likely to die of heart disease, but it is not known exactly why this is. Understanding heart disease in people with haemophilia is important because better treatments for haemophilia mean that these patients are now living longer, but doctors still don't know if the risk for heart disease in these patients as they age is the same as that for the general population. If these processes are better understand (perhaps less blood clotting is actually protecting the heart from blockage-causing clots), scientists might be able to reduce the risk of heart attacks for everybody. The UK's first photon-counting detector cardiac CT scanner generates detailed images of the heart and its blood vessels by counting individual X-ray photons. Together with artificial intelligence tools, it is possible to extract a lot of information from these images. As people age, fat is deposited in the vessels which supply blood to the heart which forms plaques. Plaques cause narrowing of the vessels, reducing blood flow to the heart, and can also burst (rupture), leading to a blood clot and heart attack. The new CT scan will show the type and amount of plaques, and quantify the risk of plaque rupture, in people with haemophilia; and the investigators will compare this to people without haemophilia. Understanding the role of factor VIII/IX in heart attacks will improve management of heart disease in people with haemophilia, and may also lead to new prevention and treatment strategies that benefit heart health for everyone.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 19 Nov 2024
- Start date
- 25 Feb 2025
- Primary completion date
- 31 Jul 2026
- Lead sponsor
- Oxford University Hospitals NHS Trust
- Diseases
- Haemophilia
- NCT number
- NCT06706206
What you commit to
- Study type: Observational
- Planned participants: 80
- From 25 Feb 2025 to the primary completion date, 31 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any other medical conditions which would influence the reliability of the study results determined by the investigators.
Lab values
- Patients with absolute contra-indications to CT imaging will be excluded from the study. This includes:
- Any known contraindications to CT iodinated Contrast.
- Significant renal impairment (eGFR \<30 ml/min).
Other
- Participants unable or unwilling to give informed consent.
- Participants unable to understand the English language.
- Participants unable or unwilling to attend for the necessary scans and investigations.
Who the study is looking for
- Be willing and able to give informed consent for participation in the study.
- Male, aged 45 years or above (no upper age limit).
- Haemophilia A or B with Factor VIII/IX less than 40% (0.40 IU/ml).
Age in the registry: 45 years to 120 years · Sex: Male
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oxford Haemophilia and Thrombosis Centre, Oxford University Hospitals NHS Foundation Trust Coordinator of this site? Confirm its status | Oxford | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.